Neuland Laboratories Board to Consider Q2 and H1 FY27 Results on 3rd Nov'26
Neuland Laboratories Ltd 路 Intimation 路 03 Nov 2026, 5:30 am
Neuland Laboratories Board to Consider Q2 and H1 FY27 Results on 3rd Nov'26 Neuland Laboratories Limited has scheduled a meeting of its Board of Directors on 3rd Nov'26 to consider and approve the standalone and consolidated unaudited financial results for the quarter and half year ended 30th Sep'26. Additionally, pursuant to the company's Insider Trading Code, the trading window for dealing in equity shares remains closed from 1st Oct'26 until 48 hours following the declaration of the financial results.
Original exchange filing (PDF)
More announcements from Neuland Laboratories Ltd
- Intimation about Schedule of Analyst / Institutional Investor Meeting on November 17, 2026 路 06 Nov 2026
- Change in Corporate Office Address of Registrar and Share Transfer Agent (RTA) 路 05 Nov 2026
- Audio Recording of the Earnings call conducted on November 3, 2026 路 04 Nov 2026
- Investor Presentation on the Financial Results of the Company for the quarter and half year ended September 30, 2026 路 03 Nov 2026
- Press Release on the Financial Results of the Company for the quarter and half year ended September 30, 2026 路 03 Nov 2026
- Disclosure under Regulation 30 of SEBI Listing Regulations 路 03 Nov 2026
- Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026 路 03 Nov 2026
- Neuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 03 Nov 2026
